TrialBlood cancer journal2021

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Paul G Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.